MicroConstants provides biomarker testing and analysis services to support preclinical and clinical diagnostic research of new therapeutics. We perform biomarker assay development, validation, and profiling of disease panels using multiplex, LC/MS/MS and ELISA techniques.
Using the Luminex platform for biomarker assay development, validation and profiling of disease panels enables us to simultaneously interrogate up to 100 analytes in each sample. Nucleic acids or protein samples are examined to detect biomarkers that correlate with the progression of a disease or success of a therapy.
Performing multiplex biomarker analysis using the Luminex platform with xMAP technology enables us to:
MicroConstants develops and validates highly selective bioanalytical methods for the simultaneous quantitation of multiple biomarker peptides or epitope peptides of monoclonal antibodies in serum or plasma matrices using Solid Phase Extraction (SPE) coupled with UPLC/MS/MS. The increased sensitivity of the Xevo TQ-S triple quadrupole mass spectrometer coupled with UPLC provides the specificity, accuracy and precision required for biomarker quantitation.
MicroConstants provides ELISA biomarker assay development and validation for biomarker identification using the following formats:
Each assay undergoes rigorous testing to ensure high precision and accuracy while also delivering the sensitivity and specificity required to detect biological levels of analytes in over 35 biological matrices including blood, serum, plasma, CSF, and tears. High-throughput screening using automated instrumentation is also available.